The components have their own evidence, but there is no established human evidence proving that this exact blend works as a combination. Direct combination evidence is shown separately when it exists.
Still uncertain: Whether the combination works better together, human benefit, safety, optimal ratio or dosing of the blend.
By confirming your subscription, you agree to receive occasional WhichPeps Evidence Updates. Kit processes the signup and email delivery for WhichPeps. Privacy. Unsubscribe anytime.
What does the evidence mean in simple terms? table
What is it?
Multi-peptide blend
Entity type
Peptide blend
Research focus
Tissue-repair and recovery claims
Human evidence
No controlled human clinical trial of the BPC-157 + TB-500 combination was identified.
Regulatory status
No approved medicine corresponding to this blend was identified.
Main limitations
Human synergy, efficacy, safety, optimal ratio or dosing of the blend.
Safety
Unknown interaction, purity and immunogenicity risks in addition to component-specific uncertainty.
Evidence reviewed
2026-09-18
i
No controlled human clinical trial of the BPC-157 + TB-500 combination was identified.
Outcome-level evidence
Evidence is not one score.
This section separates the evidence status from what the evidence actually found. Direct combination evidence is never inferred from component studies.
Evidence rule: absence of direct combination evidence is a research conclusion when the search has been documented; it is not permission to infer efficacy from the components.
Evidence synthesis
✓There is genuine combination-specific animal evidence.
Important limitations
!Small animal study; no human translation.
Selected study & evidence records
BPC-157 + TB-500 combination arm in rat Achilles tendon repair
2026 · Randomized animal experiment · n=32
The combination improved some histologic measures versus control but did not provide additional benefit over either agent alone.
Unknown interaction, purity and immunogenicity risks in addition to component-specific uncertainty.
Technical details
Mechanism / biologyCombines two investigational peptides; no validated combined mechanism or interaction profile has been established clinically.
Route / formulation boundaryTotal milligrams do not define the ratio or identity unless the product label/COA provides it.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Study / label regimen evidenceStudy-regimen evidence reviewed. No clinical regimen for the BPC-157 + TB-500 blend identified; component studies do not establish a blend dose.
WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.
1structured study records
1outcome records
6linked source records
How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.
Show supporting and discovery sources
Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.
PubMed / peer-reviewed source ↗ — Supports the statement that current component literature should not be mistaken for a studied BPC-157 + TB-500 combination.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
